Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $69.5 million.

  • Summit Therapeutics' Total Liabilities rose 698.27% to $69.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.5 million, marking a year-over-year increase of 698.27%. This contributed to the annual value of $46.8 million for FY2024, which is 6262.72% down from last year.
  • Summit Therapeutics' Total Liabilities amounted to $69.5 million in Q3 2025, which was up 698.27% from $64.6 million recorded in Q2 2025.
  • Over the past 5 years, Summit Therapeutics' Total Liabilities peaked at $537.5 million during Q4 2022, and registered a low of $22.1 million during Q3 2022.
  • For the 5-year period, Summit Therapeutics' Total Liabilities averaged around $98.1 million, with its median value being $64.9 million (2024).
  • As far as peak fluctuations go, Summit Therapeutics' Total Liabilities soared by 168635.43% in 2022, and later crashed by 7669.7% in 2023.
  • Over the past 5 years, Summit Therapeutics' Total Liabilities (Quarter) stood at $30.1 million in 2021, then surged by 1686.35% to $537.5 million in 2022, then crashed by 76.7% to $125.3 million in 2023, then plummeted by 62.63% to $46.8 million in 2024, then soared by 48.39% to $69.5 million in 2025.
  • Its last three reported values are $69.5 million in Q3 2025, $64.6 million for Q2 2025, and $39.5 million during Q1 2025.